Results 131 to 140 of about 114,702 (262)

Incidence, Prevalence, Survival and Mortality of Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma and Waldenström Macroglobulinaemia in Australia

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Background Mature B‐cell neoplasms chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) and waldenström macroglobulinaemia (WM) are highly prevalent in older populations. Aims This study quantified the incidence, prevalence and relative survival/mortality rate in Australia for CLL/SS and WM and reported the past trends. Materials
Dieu Nguyen, Shalika Bohingamu Mudiyanselage, Dipti Talaulikar, Fei‐Li Zhao, Boxiong Tang, Mostafa Kamal, Lan Gao   +6 more
wiley   +1 more source

Overcoming challenges in CAR‐T therapy for malignancies: Mechanisms and strategies

Clinical and Translational Discovery, Volume 6, Issue 1, February 2026.
Chimeric antigen receptor T (CAR‐T) cell therapy faces three major challenges: tumour‐intrinsic resistance mechanisms, limitations in CAR‐T cell efficacy and immunosuppressive tumour microenvironment (TME) effects. Emerging strategies address these hurdles through precision targeting enhancement, optimised CAR‐T cell persistence/functionality and TME ...
Yushan Huang, Jun Long, Changpeng Yang, Wang Lu, Husheng Mei, Wenbin Qian, Jing Yang, Aibin Liang   +7 more
wiley   +1 more source

The expression and signalling patterns of CD180 toll like receptor in Chronic Lymphocytic Leukaemia (CLL) [PDF]

, 2019
Chronic lymphocytic leukaemia (CLL) is characterised by a progressive accumulation of mature CD5+CD20+CD23+ lymphocytes. Despite the remarkable progress in our understanding of the immunobiology of CLL, the aetiology of the disease remains unknown.
Sayed, U., Sayed, U.
core  

Alterations in Gut Microbiota and Metabolic Profiles in Relapsed or Refractory Lymphoma

MicrobiologyOpen, Volume 15, Issue 1, February 2026.
Metabolomic volcano‐heatmap reveals seven upregulated metabolites in relapsed/refractory lymphoma, underscoring gut metabolic reprogramming as a potential therapeutic target. ABSTRACT To identify potential therapeutic strategies for relapsed or refractory lymphoma (R/RL) by examining differences in gut microbiota composition and metabolic profiles ...
Yu‐Ying Guo, Kang‐Jing Xue, Liao Wang, Gang‐Gang Wang, Ting‐Ting Zhang, Shu‐Ling Hou   +5 more
wiley   +1 more source

MicroRNA-214 targets PTK6 to inhibit tumorigenic potential and increase drug sensitivity of prostate cancer cells. [PDF]

, 2019
Prostate cancer is the most commonly diagnosed cancer in men with African American men disproportionally suffering from the burden of this disease.
Aqeel, Rasha, Cagle, Patrice, Chimeh, Uchechukwu, Collins, Sean P, Dahiya, Rajvir, Kumar, Deepak, Niture, Suryakant, Ramalinga, Malathi, Rios-Colon, Leslimar, Srivastava, Anvesha, Suy, Simeng   +10 more
core   +1 more source

Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome. [PDF]

, 2017
Pathogenesis of chronic lymphocytic leukaemia (CLL) is contingent upon antigen receptor (BCR) expressed by malignant cells of this disease. Studies on somatic hypermutation of the antigen binding region, receptor expression levels and signal capacity ...
Allen, John C, Allsup, David, Bentley, Alison, Cawkwell, Lynn, Duckworth, Andrew D, Kalakonda, Nagesh, Lin, Ke, Pettitt, Andrew R, Ringshausen, Ingo, Slupsky, Joseph R, Talab, Fatima, Till, Kathleen J   +11 more
core   +2 more sources

Tumor‐Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation

MedComm, Volume 7, Issue 2, February 2026.
Tumor‐associated macrophages are the most abundant immune cells in the tumor microenvironment, driving malignant progression and treatment resistance. This review summarizes the protumor mechanisms of TAMs (including phagocytosis modulation, metabolic reprogramming, exosomal communication, and immune interactions), evaluates three major strategies ...
Wurihan Bao, Xiaojie Qu, Yiqi Wang, Dan Huang, Huiling Zhang, Mingyuan Dong, Han Sun, Zhaogang Yang, Xuefeng Li   +8 more
wiley   +1 more source

Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption

Bone Reports, 2019
Osteoclasts are responsible for bone erosion in osteoporosis and rheumatoid arthritis (RA). Both Btk and Tec kinases have essential functions in osteoclast differentiation. Tirabrutinib is a highly potent and dual oral Btk/Tec inhibitor with an IC50 in the nmol/L range and significantly inhibits the M-CSF and RANKL-driven osteoclast differentiation. It
Yuko Ariza, Masayuki Murata, Yoshiko Ueda, Toshio Yoshizawa   +3 more
openaire   +3 more sources

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy

European Journal of Haematology, Volume 116, Issue 2, Page 104-115, February 2026.
ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Stefano Oliva, Stefano Molica
wiley   +1 more source

Transcriptome-Wide Effects of Sphingosine Kinases Knockdown in Metastatic Prostate and Breast Cancer Cells: Implications for Therapeutic Targeting [PDF]

, 2019
Sphingosine kinases 1 and 2 (SK1 and SK2) are proto-oncogenic isozymes expressed in many human tumors and associated with chemoresistance and poor prognosis.
Alshaker, Alshaker, Alshaker, Alshaker, Alshaker, Angerer, Antoon, Beljanski, Carvalho, Cuvillier, Garland, Hu, Irizarry, Jiang-Hua, Liu, Liu, Paugh, Pchejetski, Pchejetski, Permpongkosol, Pham, Pyne, Shida, Smyth, Song, Wang, Wang, Wang, White, Yee, Yu   +30 more
core   +4 more sources